Literature DB >> 6321081

Decreased oral warfarin clearance after ranitidine and cimetidine.

P V Desmond, M L Mashford, P J Harman, B J Morphett, K J Breen, Y M Wang.   

Abstract

Oxidative metabolism inhibition of a number of drugs by cimetidine has been attributed to its imidazole ring, a hypothesis that has been supported by reports that ranitidine does not affect drug metabolism despite being five times as potent as cimetidine as an H2-receptor antagonist. In five healthy subjects ranitidine at 150 mg twice daily induced a 27% fall in apparent oral warfarin clearance. In the same subjects cimetidine at 1 gm/day induced a 36% decrease in warfarin clearance. In two of the subjects the experiment was repeated after giving 750 mg ranitidine per day and in two other subjects after 200 mg cimetidine twice daily. In both instances there was a stepwise fall in warfarin clearance with increasing doses. The data indicate that interference with drug metabolism by H2-receptor antagonists is not confined to cimetidine but that on a molar basis ranitidine and cimetidine are roughly equivalent in inhibiting warfarin clearance and that the effects are related to dose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6321081     DOI: 10.1038/clpt.1984.40

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

Review 1.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism.

Authors:  G I Adebayo; H A Coker
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Cimetidine and ranitidine on basal and ACTH-stimulated steroidogenesis.

Authors:  R G Karlstadt; W O Frank; L A Antell; S W Shapowal; R H Palmer
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

Review 5.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

6.  A long lasting gastrin response to apomorphine revealed by inhibitors of gastric acid secretion.

Authors:  M Goiny; K Brodin; C E Elwin; K Uvnäs-Moberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 8.  Pharmacokinetic drug interactions in anaesthetic practice.

Authors:  M Wood
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

9.  Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans.

Authors:  R Bendayan; J T Sullivan; C Shaw; R C Frecker; E M Sellers
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 10.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.